Abstract
Introduction

Proteoglycans were found to be involved in cancer biology over 50 years ago. Initially, pathologists noted that some carcinomas induce a desmoplastic hyperproliferative-like reaction within the host stroma and the connective tissue surrounding the cancer cells. Often this reaction stains metachromatically with cationic dyes such as alcian blue indicating a high glycosaminoglycan, and
thus proteoglycan, content in the desmoplastic reaction. Given the fact that desmoplasia occurs in tumours with diverse histogenetic backgrounds [1] , it seems plausible to consider this abnormal expression of proteoglycans a sort of general 'reaction to invasion' with agonistic and antagonistic elements embedded in the same stroma [2] . With the advancement of molecular and cellular biology, [3] . In contrast, C-terminal fragments of other proteoglycans counteract the angiogenic process by blocking the activity of several integrins necessary for endothelial cell movement [4] [5] [6] . The structural and functional characterization of cell surface heparan sulphate proteoglycans over the last two decades has led to an understanding of the broad impact these molecules have on cell behaviour [7] . Both the syndecan and glypican family have been implicated as regulators of cancer progression and in addition may serve as biomarkers for early detection or severity of disease [8] [9] [10] . Interestingly, the emerging data indicate that cell surface heparan sulphate proteoglycans may play diverse roles in cancer and act as either inhibitors or promoters of tumour progression depending on the type and stage of cancer. In addition, the function of these proteoglycans can be altered by two classes of enzymes within the tumour microenvironment, those that can release proteoglycans from the cell surface (sheddases) and those that can modify the structure of heparan sulphate chains (heparanases and endosulfatases) [11, 12] . Thus, the expression of these enzymes can act as a mechanism to dynamically control proteoglycan location and function and thus, tumour cell behaviour [9] . [14, 15] . In this review we will discuss examples of both HSPGs and SLRPs to critically assess their roles in cancer biology, tumour microenvironment and angiogenesis. [4, 22] . Its promoter region is quite complex [23] [99] .
Another class of proteoglycans carrying primarily dermatan or chondroitin sulphate, the so-called small leucine-rich proteoglycans (SLRPs), act as tumour repressors by blocking the activity of receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor (EGFR) and Met [13]. In addition some of the SLRPs interact with integrins and Toll receptors and modulate adhesion and innate immunity
Perlecan: a pro-angiogenic proteoglycan
Perlecan is a complex modular proteoglycan consisting of five domains with homology to growth factors, immunoglobulin and adhesion molecules [16-20] and encoded by a very large gene encompassing 95-97 exons [21]. Its biology is complicated by the large number of post-translational modifications including potential substitution with three heparan sulphate chains at the N-terminus, several O-linked oligosaccharides throughout the large protein core and the potential substitution with chondroitin sulphate
In summary, C-terminal fragments of perlecan, either endorepellin or its terminal LG3 module, can act as a powerful anti-angiogenic factor by interacting with the ␣2I domain of the ␣2␤1 integrin. This unique interaction triggers a signal cascade that leads to disruption of endothelial cytoskeleton and endothelial cell motility (Fig. 1). Endorepellin also activates the tyrosine phosphatase SHP-1 which is bound to the cytoplasmic domain of the ␣2␤1 integrin. SHP-1 then dephosphorylates a number of RTKs including VEGFR2, thereby blocking endothelial cell migration, survival and proliferation.
Syndecans in cancer biology
The syndecans are a family of transmembrane proteoglycans that bear predominantly heparan sulphate glycosaminoglycan chains [100, 101] . The core proteins consist of a short intracellular domain, a transmembrane domain that is highly conserved, and an ectodomain that is divergent in amino acid sequence among the four syndecan family members [100] . Syndecans are expressed ubiquitously throughout embryonic development and adulthood, although the individual syndecans exhibit differing patterns of expression. Importantly, the pattern of expression and/or the structure of heparan sulphate is altered in response to certain pathophysiological stimuli and this in turn can regulate tumour progression [7, 102] [100] . Transformed epithelial cells often lose expression of syndecan-1 and E-cadherin which together appear to be key steps in regulating epithelial to mesenchymal transition [106, 107] . This likely explains why loss of syndecan-1 expression is associated with accelerated tumour progression and reduced patient survival in some types of carcinomas [108, 109] . Conversely, in other tumour types such as breast carcinoma and haematological malignancies, syndecan-1 is often highly expressed and associated with increased tumour invasiveness and poor prognosis [110] [111] [112] [113] [114] growth, adhesion and migration [9] . Myeloma cell lines expressing low levels of syndecan-1 grow poorly in vivo, whereas their counterparts expressing elevated levels of syndecan-1 grow very aggressively and form large, highly vascular tumours [115] . In addition to its expression by tumour cells, syndecan-1 expressed by stromal cells can also impact tumour behaviour. In breast cancer syndecan-1 is present in high levels in the stroma of some patients and stromal expression has been correlated with poor prognosis [116, 117] . Moreover, studies in mouse models have demonstrated that stromal syndecan-1 released into the tumour microenvironment enhances breast tumour growth and angiogenesis [118, 119] . [120] . Further studies probing the mechanism of syndecan-1 activity in tumorigenesis indicate that the proteoglycan may be required for the activation of tumour precursor cells that arise within the stem/progenitor cell compartment [121, 122] [124] . Interestingly, although it has been known for some time that syndecan-1 promotes tumour cell binding to type I collagen and inhibits its invasion into collagen gels [125] , a series of recent studies identify syndecan-1 as a co-receptor for ␣2␤1 integrin-mediated adhesion to collagen [126, 127] [134, 135] . These adhesion and migration functions of syndecan-2 appear to be, at least in part, due to its functioning as a co-receptor for ␣2␤1 integrin because knockdown of the ␣2 integrin chain on HCT116 colon carcinoma cells diminished syndecan-2-induced cell migration [136] . Also, a recent report indicates that the cell migration promoted by syndecan-2 occurs through Tiam1-mediated activation of Rac [137] . [138] . Additional evidence of a role for syndecan-2 in angiogenesis has come from knockdown experiments in zebrafish where it appears that syndecan-2 may act as a co-receptor for VEGF [139] . [140] and is down-regulated on invasive colon carcinoma cells [135, 141] [142] . In contrast, a different study reports that diminishing syndecan-4 expression caused a decrease in melanoma cell invasion by decreasing Wnt5A signalling [143] . This suggests that syndecan-4 can play differing roles in tumour invasive potential depending on the factor(s) that are present to regulate motile behaviour. Also, complexing of syndecan-4 with FGF-2/FGFR-1 promotes pro-angiogenic signalling events through the protein kinase C␣ pathway [144] . [145] . Thus, regulation of cell adhesion via syndecan-4 is critical in controlling both the migration and proliferation of some tumour types. [149] [150] [151] .
In addition to regulating tumour growth and metastasis, studies with syndecan-1 null mice indicate that this proteoglycan may also be critical for initial steps leading to initiation of tumours. Crossing Wnt transgenic mice that normally have a high incidence of spontaneous breast tumour formation with syndecan-1 null mice results in a dramatic reduction in tumour formation
In addition to its effects in tumour cells, syndecan-2 may also enhance angiogenesis. Syndecan-2 is highly expressed in the microvessels of mouse glioma tumours and when syndecan-2 expression is knocked down in brain microvascular endothelial cells both cell migration and in vitro capillary tube formation are inhibited
Syndecan-4 is reportedly expressed at some level by most tumours and also within the tumour microenvironment. In contrast to syndecan-2 which enhances migration of tumour cells, syndecan-4 is similar to syndecan-1 in that it mediates tumour cell adhesion to extracellular matrix and inhibits cell invasion in some cancers. Syndecan-4 mediates adhesion and spreading of breast cancer cell lines
. Diminished expression of syndecan-4 in melanoma cells resulted in down-regulation of FGF-2 signalling leading to an increase in tumour cell motility and decreased adhesion to fibronectin
Disruption of interactions between syndecan-4 and fibronectin by the extracellular matrix molecule tenascin-C decreases focal adhesions on tumour cells leading to increased tumour cell proliferation
Glypicans and the control of cancer growth
Within the context of human malignancies, glypican-3 has been studied most extensively within the glypican family members [146, 149, 152] [153] , lung [154] , ovary [155] or mesothelium [156] [171, 172] .
. Glypican-3 expression and function correlate with tumour type and cell of origin and thus analysis of glypican-3 can aid in the diagnosis and prognosis of some cancers. In cancers of the breast
It has become increasing clear that shedding of proteoglycans from the surface of cells plays an important role in regulating proteoglycan localization and function [11] . Shedding occurs through the activity of various MMPs which clip the core proteins of proteoglycans and release functional ectodomains [173] [185, 186] (Fig. 2) (Fig. 2) . These multifunctional activities of heparanase are consistent with is known roles in regulating tumour growth, angiogenesis and metastasis.
occurs via heparanase stimulation of ERK signalling with a resulting increase in expression of MMP-9, a protease that acts as a sheddase for syndecan-1 [184]. Up-regulation of heparanase expression in myeloma cells also leads to enhanced expression of VEGF and HGF, two factors that bind to the shed syndecan-1 and form complexes that stimulate angiogenesis and tumour growth
Decorin and growth control
Decorin is a prototype member of the SLRPs, an expanding family of about 18 homologous genes that encompass five distinct classes [14, 187, 188] . Decorin received its eponym because of its ability to 'decorate' collagen fibres [189] at specific sites [190] and to regulate fibrillogenesis both in vitro [191] and in vivo [192] . Decorin is also known to regulate growth factor bioactivity [193, 194] . The decorin-null animals are fertile and viable but show abnormal collagen architecture, most pronounced in the dermis, which causes a decrease tensile strength of the skin with a consequent skin fragility phenotype [192] . The initial observation linking decorin to growth control derives from studies using [195] . It was subsequently found that decorin secreted by the transgenic CHO cells bound with high affinity to TGF-␤ thereby blocking the growth-stimulatory activity of the growth factor [196] . The second observation linking decorin to cell growth emerged from studies focusing on the identification of differentially expressed genes in quiescence versus growing cells. These studies showed that the mRNA levels of decorin, one of the eight most up-regulated genes, increased several folds during quiescence [197] . In vitro transcriptional analysis indicated enhanced transcriptional activity in quiescent fibroblasts when compared to cells harvested in their logarithmic growth phase [198] . [199, 200] 
Chinese Hamster Ovary (CHO) cells which are unique because their growth is dependent on TGF-␤ secreted as an autocrine factor. These decorin-expressing CHO cells formed a more orderly monolayer and grew to a lower saturation density than control cells lacking decorin, and these changes correlated with the levels of decorin expression
The third line of evidence for a direct involvement of decorin in growth control is based on the fact that de novo expression of decorin suppresses the malignant phenotype in a wide variety of transformed cells
and the effects are mediated by decorin-evoked induction of the cyclindependent kinase inhibitor p21
WAF1/CIP1 (p21) [201] . [209, 210] . Notably, the EGFR could be identified as an interacting partner for decorin using interaction cloning and the yeast two-hybrid system [211] . [211] . [212] . Biologically active decorin is likely to act as monomer in solution [215] and adenoviral gene delivery of decorin has been shown to inhibit in vivo tumorigenicity and metastatic spreading [205, [216] [217] [218] [219] [220] . Analogously, systemic delivery of decorin proteoglycan or decorin protein core inhibits tumour growth in various xenografts models, including squamous, breast and prostate carcinomas [208, 221, 222] [221] . [1, 223, 224] could indeed represent a protective mechanism, a sort of soluble tumour repressor, that could counteract in vivo tumour cell growth [225] . The recent report of reduced plasma decorin in oesophageal cancer patients suggests that plasma decorin could represent a novel biomarker for cancer recognition and prognosis [226] .
Induction of endogenous p21 has now been recorded in a number of experimental settings utilizing recombinant decorin, adenoviral gene delivery or stable transfection of decorin, both in normal and malignant cells [202-208]. It became apparent, however, that the growth of several of the tumour cells lines that responded to decorin did not depend on the presence of TGF-␤ or its downstream signalling like the original CHO cells mentioned above. A search for specific receptors for decorin revealed that decorin suppresses tumour cell growth by interacting with the epidermal growth factor receptor (EGFR)
Decorin binds to a narrow region of the EGFR that is partially overlapping but distinct from the EGF-binding domain
Decorin/EGFR interaction leads to a sustained down-regulation of the EGFR [212] and, in mammary carcinoma cells, decorin also interacts with ErbB4 and indirectly down-regulates ErbB2, presumably by down-regulating of ErbB2/ErbB4 heterodimers [213]. Decorin evokes protracted internalization of the EGFR via caveolar endocytosis rather than clathrin-mediated endocytosis as EGF usually does [214]. This leads to a profound physical downregulation of the EGFR with consequent reduction of receptor number rather than affinity
. The in vivo effects of decorin, when tested, show a concomitant down-regulation of the EGFR in the tumour xenografts and induction of apoptosis, predominantly through activation of caspase-3
Collectively, these studies indicate that decorin is a component of the circuit that regulates growth of eukaryotic cells. The reported overexpression of decorin in the stroma of a variety of solid tumours
Genetic evidence for a role for decorin in carcinogenesis
The human decorin gene is quite complex with two alternativelyspliced exons, potentially two distinct promoters [227] [228] [229] and its expression in colon cancer is regulated by methylation of its control regions [1, 230] . The original decorin null mice were generated in a mixed genetic background of 129/Sv and BL/Swiss [192] 
Mechanism of decorin action: suppression of ␤-catenin and Myc levels
The complex binding repertoire of decorin suggests that this proteoglycan might interact with other RTKs in addition to EGFR and ErbB4 [188] . Using an antibody array detecting 42 Tyrosine phosphorylated RTKs it was recently found that exogenous decorin binds to Met, the HGF receptor, and stimulates a process that leads to receptor down-regulation and shedding, both contributing to attenuation of Met signalling pathway [233] . [188] . In addition, Myc, a downstream target of ␤-catenin, was markedly down-regulated by decorin, whereas phosphorylation of Myc at Thr58 was markedly induced [234] . The latter is known to destabilize Myc and target it for proteasomal degradation [235] . We also discovered that systemic delivery of decorin using three distinct tumour xenograft models caused downregulation of Met and a concurrent suppression of ␤-catenin and Myc levels [234] .
Of note, human recombinant decorin proteoglycan and protein core induce a protracted suppression of intracellular ␤-catenin, a known downstream effector of Met, and concurrently inhibit cell growth. A recent study has shown that decorin blocks several biological activities mediated by the Met signalling axis, including cell scatter, evasion and migration. These effects were mediated by a profound down-regulation of non-canonical ␤-catenin levels
It is well established that there is a positive feedback loop between HGF/Met axis and ␤-catenin in sustaining the growth of several malignant tumours [236] [237] [238] . In addition, HGF induces Wnt-independent nuclear translocation of ␤-catenin following Met/␤-catenin dissociation in hepatocytes [239] . (Fig. 3A) . Both ␤-catenin and Myc translocate to the nucleus where they activate a large number of genes including Myc itself [240, 241] , thereby establishing a positive feedback loop that favours growth and survival (Fig. 3A) . (Fig. 3B) [233] . The concurrent induction of phosphorylated Thr58 in Myc and its down-regulation at the protein and transcriptional levels [234] indicate that this is also a consequence of decorin-evoked suppression of RTK activity.
Under growing conditions, ␤-catenin and Myc are stabilized by activation of the Wnt signalling and various RTK pathways which are often hyperactive in cancer. Activation of Wnt and RTK pathways leads to phosphorylation of glycogen synthase kinase-3␤ (GSK-3␤) which causes an inactivation of this important serine-threonine kinase and a concurrent release of active ␤-catenin and Myc
Among the genes that are induced by Myc is activating enhancer-binding protein (AP)4, a transcriptional repressor of p21 [242], which also enhances the proliferative potential of transformed cells. Decorin, by neutralizing the activity of RTKs such as EGFR and Met, releases GSK-3␤ from being phosphorylated and thus inactivated. This leads to GSK-3␤ evoked phosphorylation of both ␤-catenin and Myc at specific sites that lead to recognition by ubiquitin ligases and degradation within the 26S proteasome
Lumican in cancer biology
Lumican is a keratan sulphate SLRP that participates in the acquisition of corneal transparency, hence its eponym, by regulating collagen fibril diameter and interfibrillar spacing [244, 245] . However, various forms of lumican often carrying polylactosamine chains, variants of undersulphated keratan sulphate, have been reported in various tissues outside of the cornea. Notably, lumican expression is increased in breast cancer, especially in the tumour stroma, and this correlates with higher tumour grade and lower oestrogen receptor levels [246] . More recently, lumican expression has been reported to be altered in various types of human malignancies, including melanomas [247, 248] , osteosarcomas [249] , pulmonary [250] , pancreatic [251, 252] and colorectal carcinomas [253] . However, there are contrasting reports regarding the role of lumican in terms of potential biological function, i.e. pro-or antioncogenic role, and prognostic indicator. For example, in some studies lumican overexpression correlates with poor prognosis in advanced colorectal [253] and pancreatic [251] cancers. Similarly, in lung adenocarcinomas and squamous cell carcinomas lumican expression correlates with poor outcome [250] . It is not clear, however, whether the elevated expression of lumican in the tumour stroma would correlate with poor prognosis because of more invasive tumours or because lumican is indeed a biomarker for poor outcome. One possibility is that the poor prognosis might be related to the abundance of tumour stroma which is indicative of more advanced neoplasms. In contrast, lumican might play an opposite role in osteosarcomas where its expression correlates positively with differentiation and negatively with tumour progression [249] . In melanomas, stroma lumican levels decrease markedly with increasing malignancy as measured by vertical growth of the melanomas [247] . Moreover, B16F1 melanoma cells engineered to express lumican showed a marked reduction in the number and sizes of the pulmonary tumour nodules as compared to the wild-type cells [254, 255] , suggesting that lumican might indeed be an anti-oncogenic agent. This concept is supported by a mechanistic study which has shown that de novo expression of lumican inhibits focus formation in cells transformed with the potent H-ras oncogene [256] . Moreover, colony formation in soft agar, a hallmark of malignant transformation, induced by the two viral oncogenes v-K-ras and v-src is suppressed in cells stably expressing lumican, without affecting cell proliferation [256] . [257] . Analogous to decorin, lumican-mediated cytostatic effects on cancer cells are associated with an induction of the cyclin-dependent kinase (CDK) inhibitor p21 WAF1 [257] . [259] , it regulates neutrophil infiltration in experimental keratitis [260] and is required for neutrophil extravasation following corneal damage and inflammation [261] . Lumican adherent to the cell surface of neutrophils enhances their migration by interacting with ␤2-containing integrins [262] . In contrast, in melanoma cells lumican binds to ␤1-containing integrin receptors [263] and inhibits their migration by disrupting focal adhesion complexes [264] . The active site within the lumican protein core has been mapped to LRR9 and named lumcorin [265] . Several components of focal adhesion complexes, including vinculin and focal adhesion kinase, are modulated by lumican which leads to a disruption of the relationship between actin filaments and ␤1 integrin. Indeed, lumican protein core can directly bind the ␣2 I domain of the ␣2␤1 integrin receptor on melanoma cells with relatively high affinity [266] . Thus, the reported anti-adhesive properties of lumican could be mediated by a specific interaction with the ␣2␤1 integrin receptor, thereby providing a plausible explanation for the anti-invasive properties of this SLRP [264] . Finally, a recent study has shown that lumican can block not only melanoma invasion and metastasis, but it also can also induce tumour cell apoptosis and inhibit angiogenesis [255] . Collectively [267, 268] has led to speculation that proteoglycans may play direct roles in regulating transcription of genes that control tumour behaviour. This exciting possibility remains to be explored.
These findings suggest that lumican might be able to selectively inhibit transformation by v-K-ras and v-src viral oncogenes. In support of these studies, cleavage of lumican by membrane type 1 metalloprotease (MT1-MMP) abrogates lumican-ability to suppress colony formation in soft agar
The SLRPs have emerged as powerful signalling molecules that control a wide variety of processes and could represent novel therapeutic modalities against cancer [188] as well as being targets themselves [269] . Deciphering 
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